Presidio Pharmaceuticals, Inc.

Clinical & Science Advisory Board

Douglas Richman, M.D., Professor of Pathology and Medicine at UCSD, Director of the Research Center for AIDS and HIV infection at the VA San Diego Healthcare System, and Director of the Center for AIDS Research at UCSD. Dr Richman has investigated HIV disease and pathogenesis for the past 20 years and was the first to identify HIV drug resistance.

Edward Arnold, Ph.D., Professor II of Chemistry and Chemical Biology, Rutgers University. Dr. Arnold and his colleagues are working to develop and apply structure-based drug and vaccine designs for the treatment and prevention of serious human diseases. Dr. Arnold’s team solved the three-dimensional structures of HIV-1 RT in complex with antiviral drugs and pieces of the HIV genome, including new NNRTI candidates from Tibotec.

Jeffrey S. Glenn, M.D., Ph.D., Assistant Professor of Medicine, Stanford University School of Medicine. Director of the Center for Hepatitis & Liver Tissue Engineering at Stanford University. Dr. Glenn’s clinical focus is gastroenterology and hepatology. He is the recipient of numerous Research & Clinical Awards including the Burroughs Wellcome Fund Clinical Scientist Award for Translational Research.

Richard Ogden, Ph.D., Joining Agouron Pharmaceuticals, Inc. at its inception in 1984, Dr. Ogden held positions of Group Leader, Medicinal Chemistry; Principal Scientist, and Senior Director of Scientific Development. He served as the scientific liaison for the Agouron/Pfizer commercial & corporate organizations, assisting in the launch of, and continued support of the protease inhibitor Viracept.

Michael Bukrinsky, M.D., Ph.D., Professor and Vice Chair in the Department of Microbiology and Tropical Diseases, George Washington University Medical Center. He is the world’s foremost expert on the use of nuclear entry inhibitors for treating HIV infections and has authored more than 70 papers, primarily on HIV-1 infections. He is a member of the New York Academy of Sciences and American Society for Biochemistry and Molecular Biology.

Michael Kahn, Ph.D., Provost’s Professor of Medicine and Pharmacy at the University of Southern California (USC) with a joint appointment in the Department of Biochemistry and Molecular Biology at the Keck School of Medicine and the Department of Pharmacology and Pharmaceutical Sciences in the School of Pharmacy. Prior to joining USC, Dr. Kahn was the Scientific Director at the Institute for Chemical Genomics and a Professor at the University of Washington. He was the scientific founder of Molecumetics, a drug discovery company that developed small molecule mimics of large proteins. Dr. Kahn has emerged as a leader in the study of chemical genomics, which uses small molecules to dissect complex signaling pathways. Dr. Kahn received his Ph.D. from Yale University and performed his undergraduate studies at Columbia University.

	Management \| Board of Directors \| Clinical & Science Advisory Board
	Clinical & Science Advisory Board Douglas Richman, M.D., Professor of Pathology and Medicine at UCSD, Director of the Research Center for AIDS and HIV infection at the VA San Diego Healthcare System, and Director of the Center for AIDS Research at UCSD. Dr Richman has investigated HIV disease and pathogenesis for the past 20 years and was the first to identify HIV drug resistance. Edward Arnold, Ph.D., Professor II of Chemistry and Chemical Biology, Rutgers University. Dr. Arnold and his colleagues are working to develop and apply structure-based drug and vaccine designs for the treatment and prevention of serious human diseases. Dr. Arnold’s team solved the three-dimensional structures of HIV-1 RT in complex with antiviral drugs and pieces of the HIV genome, including new NNRTI candidates from Tibotec. Jeffrey S. Glenn, M.D., Ph.D., Assistant Professor of Medicine, Stanford University School of Medicine. Director of the Center for Hepatitis & Liver Tissue Engineering at Stanford University. Dr. Glenn’s clinical focus is gastroenterology and hepatology. He is the recipient of numerous Research & Clinical Awards including the Burroughs Wellcome Fund Clinical Scientist Award for Translational Research. Richard Ogden, Ph.D., Joining Agouron Pharmaceuticals, Inc. at its inception in 1984, Dr. Ogden held positions of Group Leader, Medicinal Chemistry; Principal Scientist, and Senior Director of Scientific Development. He served as the scientific liaison for the Agouron/Pfizer commercial & corporate organizations, assisting in the launch of, and continued support of the protease inhibitor Viracept. Michael Bukrinsky, M.D., Ph.D., Professor and Vice Chair in the Department of Microbiology and Tropical Diseases, George Washington University Medical Center. He is the world’s foremost expert on the use of nuclear entry inhibitors for treating HIV infections and has authored more than 70 papers, primarily on HIV-1 infections. He is a member of the New York Academy of Sciences and American Society for Biochemistry and Molecular Biology. Michael Kahn, Ph.D., Provost’s Professor of Medicine and Pharmacy at the University of Southern California (USC) with a joint appointment in the Department of Biochemistry and Molecular Biology at the Keck School of Medicine and the Department of Pharmacology and Pharmaceutical Sciences in the School of Pharmacy. Prior to joining USC, Dr. Kahn was the Scientific Director at the Institute for Chemical Genomics and a Professor at the University of Washington. He was the scientific founder of Molecumetics, a drug discovery company that developed small molecule mimics of large proteins. Dr. Kahn has emerged as a leader in the study of chemical genomics, which uses small molecules to dissect complex signaling pathways. Dr. Kahn received his Ph.D. from Yale University and performed his undergraduate studies at Columbia University.